Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from GH Research ( (GHRS) ) is now available.
GH Research PLC presented data from its GH001-TRD-201 clinical trial at the European College of Neuropsychopharmacology annual meeting in Amsterdam, held from October 11-14, 2025. The presentation highlighted the long-term efficacy and safety of GH001 in patients with treatment-resistant depression, showing potential for rapid remission of depressive symptoms. This development could significantly impact the treatment landscape for TRD, addressing a major unmet need in psychiatry.
The most recent analyst rating on (GHRS) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC operates in the pharmaceutical industry, focusing on developing innovative treatments for mental health disorders. The company is particularly involved in creating therapies for treatment-resistant depression (TRD) using compounds like GH001, a synthetic form of mebufotenin designed for pulmonary inhalation.
Average Trading Volume: 309,209
Technical Sentiment Signal: Buy
Current Market Cap: $780.9M
For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.